A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910